Farnesoid X receptor modulators 2014-present: a patent review

References

• Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365.
   PubMed Web of Science ®Google Scholar
• Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284:1365–1368.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999;3:543–553.
   PubMed Web of Science ®Google Scholar
• Eloranta JJ, Meier PJ, Kullak-Ublick GA. Coordinate transcriptional regulation of transport and metabolism. Methods Enzymol. 2005;400:511–530.
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterol. 2004;126:322–342.
   PubMed Web of Science ®Google Scholar
• Chiang JYL. Bile acids: regulation of synthesis. J Lipid Res. 2009;50:1955–1966.
   PubMed Web of Science ®Google Scholar
• Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6:517–526.
   PubMed Web of Science ®Google Scholar
• Song KH, Ellis E, Strom S, et al. Hepatocyte growth factor signaling pathway inhibits cholesterol 7alpha-hydroxylase and bile acid synthesis in human hepatocytes. Hepatol. 2007;46:1993–2002.
   PubMed Web of Science ®Google Scholar
• Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217–225.
   PubMed Web of Science ®Google Scholar
• Owen BM, Mangelsdorf DJ, Kliewer SA. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab. 2015;26:22–29.
   PubMed Web of Science ®Google Scholar
• Kuipers F, Claudel T, Sturm E, et al. The farnesoid X receptor (FXR) as modulator of bile acid metabolism. Rev Endocr Metab Disord. 2004;5:319–326.
   PubMed Web of Science ®Google Scholar
• Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102:731–744.
   PubMed Web of Science ®Google Scholar
• Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinol. 2005;146:984–991.
   PubMed Web of Science ®Google Scholar
• Cipriani S, Mencarelli A, Palladino G, et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in zucker (FA/FA) obese rats. J Lipid Res. 2010;51:771–784.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Rizzo G, Donini A, et al. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med. 2007;13:298–309.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Mencarelli A, Palladino G, et al. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci. 2009;30:570–580.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Cipriani S, Mencarelli A, et al. Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med. 2010;10:579–595.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Cipriani S, Baldelli F, et al. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res. 2010;49:171–185.
   PubMed Web of Science ®Google Scholar
• Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med. 1998;339:12–27.
   PubMed Web of Science ®Google Scholar
• Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–690.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Distrutti E. Bile acid-activated receptors, intestinal microbiota and the treatment of metabolic disorders. Trends Mol Med. 2015;21:702–714.
   PubMed Web of Science ®Google Scholar
• Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother. 2016;26:1–10.
   Google Scholar
• Pellicciari R, Gioiello A, Costantino G. Potential therapeutic applications of Farnesoid X Receptor (FXR) modulators. Expert Opin Ther Pat. 2006;16:333–341.
   Web of Science ®Google Scholar
• Crawley ML. Farnesoid X receptor modulators: a patent review. Expert Opin Ther Pat. 2010;20:1047–1057.
   PubMed Web of Science ®Google Scholar
• Sepe V, Distrutti E, Fiorucci S, et al. Farnesoid X receptor modulators (2011–2014): a patent review. Expert Opin Ther Pat. 2015;25(8):885–896.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Mencarelli A, Distrutti E, et al. Targeting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr Med Chem. 2010;17:139–159.
   PubMed Web of Science ®Google Scholar
• Xu Y. Recent progress on bile acid receptor modulators for treatment of metabolic diseases. J Med Chem. 2016;59:6553–6579.
   PubMed Web of Science ®Google Scholar
• Sepe V, Renga B, Festa C, et al. Modification on ursodeoxycholic acid (UDCA) scaffold. Discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). J Med Chem. 2014;57:7687–7701.
   PubMed Web of Science ®Google Scholar
• Intercept Pharmaceuticals. Preparation, uses and solid forms of obeticholic acid. WO 2013192097. 2013.
   Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6-alpha-etyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569–3572.
   PubMed Web of Science ®Google Scholar
• Zentiva KS, Rep C. Crystalline forms of obeticholic acid. rWO2017008773. 2017.
   Google Scholar
• Intercept Pharmaceuticals. Preparation and uses of obeticholic acid. WO2017111979. 2017.
   Google Scholar
• Concert Pharmaceuticals. Deuterated obeticholic acid for treating diseases that are beneficially treated by farnesoid X receptor agonists. WO2016168553. 2016.
   Google Scholar
• Intercept Pharmaceuticals. Pharmaceutical compositions for combination therapy comprising farnesoid X receptor agonist and a therapeutic agent that lowers the glucose level in blood, stimulates insulin secretion, and/or increases insulin sensitivity. WO2016164413. 2016.
   Google Scholar
• Mason A, Luketic V, Lindor K, et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid. J Hepatol. 2010;52:S1–S2.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2014;S0140–6736:61933–61934.
   Google Scholar
• FDA Drug Safety Communication. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm594941.htm
   Google Scholar
• FDA Adverse Event Reporting System (FAERS) Public Dashboard. Available from: https://fis.fda.gov/sense/app/777e9f4d-0cf8-448e-8068-f564c31baa25/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis
   Google Scholar
• Maruyama T1, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298:714–719.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Passeri D, De Franco F, et al. Discovery of 3α,7α,11β-trihydroxy-6α-ethyl-5β-cholan-24-oic acid (TC-100), a novel bile acid as potent and highly selective FXR agonist for enterohepatic disorders. J Med Chem. 2016;59:9201–9214.
   PubMedGoogle Scholar
• Alemi F, Kwon E, Poole DP, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest. 2013;123:1513–1530.
   PubMed Web of Science ®Google Scholar
• D’Amore C, F S DL, Sepe V, et al. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. J Med Chem. 2014;57:937–954.
   PubMed Web of Science ®Google Scholar
• Bar Pharmaceuticals S.r.l. Preparation of cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases. WO2015181275. 2015.
   Google Scholar
• Sepe V, Festa C, Renga B, et al. Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists. Sci Rep. 2016;6:19008.
   PubMed Web of Science ®Google Scholar
• Intercept Pharmaceuticals. 3-Desoxy derivative and pharmaceutical compositions thereof. WO2017156024. 2017.
   Google Scholar
• Intercept Pharmaceuticals. Farnesoid X receptor modulators. WO2017062763. 2017.
   Google Scholar
• Finamore C, Festa C, Renga B, et al. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands. Sci Rep. 2016;6:29320.
   PubMed Web of Science ®Google Scholar
• TesPharma S.r.l. 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid X receptor modulators. WO 2014184271. 2014.
   Google Scholar
• Intercept Pharmaceuticals. Preparation of bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions. WO2008002573. 2008.
   Google Scholar
• Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439:484–489.
   PubMed Web of Science ®Google Scholar
• Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10:167–177.
   PubMed Web of Science ®Google Scholar
• Parker HE, Wallis K, Le Roux CW, et al. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol. 2012;165:414–423.
   PubMed Web of Science ®Google Scholar
• Miyazaki-Anzai S, Masuda M, Levi M, et al. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PLoS One. 2014;9:e108270.
   PubMed Web of Science ®Google Scholar
• Wang X, Herman-Edelstein M, Levi J, et al. Dual activation of FXR and TGR5 by INT-767 mediates protection from diabetic nephropathy and retinopathy. Am J Soc Nephrol. 2015;26:169A.
   Google Scholar
• McMahan RH, Wang XX, Cheng LL, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem. 2013;288:11761–11770.
   PubMed Web of Science ®Google Scholar
• Cipriani S, Renga B, D’Amore C, et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling. PLoS One. 2015;10:e0129866.
   PubMed Web of Science ®Google Scholar
• Carino A, Cipriani S, Marchianò S, et al. BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. Sci Rep. 2017;7:42801.
   PubMed Web of Science ®Google Scholar
• Enanta Pharmaceuticals. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof. WO2016086169. 2016.
   Google Scholar
• Enanta Pharmaceuticals. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof. WO2016073767. 2016.
   Google Scholar
• Enanta Pharmaceuticals. Methods of preparation of bile acid analogs and use thereof as FXR/TGR5 agonists. WO2016130809. 2016.
   Google Scholar
• Enanta Pharmaceuticals. Preparation of bile acid derivatives as FXR/TGR5 agonists and methods of use thereof. WO2016086218. 2016.
   Google Scholar
• Enanta Pharmaceuticals. Preparation of deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof. WO2017147159. 2017.
   Google Scholar
• Enanta Pharmaceuticals. Methods of preparation of bile acid derivatives and use thereof as FXR/TGR5 agonists. WO2016161003. 2016.
   Google Scholar
• Enanta Pharmaceuticals. Preparation of tetrazole derivatives of bile acids useful as FXR/TGR5 agonists. US20160145295. 2016.
   Google Scholar
• Xiao H, Li P, Li X, et al. Synthesis and biological evaluation of a series of bile acid derivatives as FXR agonists for treatment of NASH. ACS Med Chem Lett. 2017;8(12):1246–1251.
   PubMed Web of Science ®Google Scholar
• Maloney PR, Parks DJ, Haffner CD, et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem. 2000;43:2971–2974.
   PubMed Web of Science ®Google Scholar
• Evaluating the safety, tolerability, and efficacy of GS-9674 in participants with nonalcoholic steatohepatitis (NASH), responsible party: Gilead sciences, clinicaltrials.Gov identifier. NCT02854605. Available from: https://clinicaltrials.gov/ct2/show/NCT02854605
   Google Scholar
• Gilead Sciences. Novel FXR (NR1H4) modulating compounds. WO201696116. 2016.
   Google Scholar
• Sunshine Lake Pharma Co. Tricyclic compounds and uses thereof medicines. WO2016127924. 2016.
   Google Scholar
• Alios Biopharma, Inc. FXR modulators and methods of their use. WO2017147047. 2017.
   Google Scholar
• Gilead Sciences. Hydroxy containing FXR (NR1H4) modulating compounds. WO201696115. 2016.
   Google Scholar
• Novartis AG Azabicyclooctane derivatives as FXR agonists for use in the treatment of liver and gastrointestinal diseases. WO201697933. 2016.
   Google Scholar
• Novartis AG Methods for using FXR agonists. WO2017145031. 2017.
   Google Scholar
• Novartis AG Methods for using FXR agonists. WO2017145040. 2017.
   Google Scholar
• Novartis AG Methods for using FXR agonists. WO2017145041. 2017.
   Google Scholar
• A multipart, double blind study to assess safety, tolerability and efficacy of LJN452 in PBC patients. responsible party: Novartis Pharmaceuticals, clinicaltrials.gov identifier. NCT02516605. Available from: https://clinicaltrials.gov/ct2/show/NCT02516605
   Google Scholar
• Safety, tolerability and efficacy study of 12 weeks LJN452 treatment in NASH patients (FLIGHT-FXR). Responsible party: Novartis Pharmaceuticals, clinicaltrials.gov identifier. NCT02855164. Available from: https://clinicaltrials.gov/ct2/show/NCT02855164
   Google Scholar
• Enanta Pharmaceuticals. Isoxazole derivatives as FXR agonists and methods of use thereof. WO2017189651. 2017.
   Google Scholar
• Enanta Pharmaceuticals. Isoxazole derivatives as FXR agonists and methods of use thereof. WO2017189652. 2017.
   Google Scholar
• Nicolaou KC, Evans Ronald M, Roecker AJ, et al. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org Biomol Chem. 2003;1:908–920.
   PubMed Web of Science ®Google Scholar
• Downes M, Verdecia MA, Roecker AJ, et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell. 2003;11:1079–1092.
   PubMed Web of Science ®Google Scholar
• Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med. 2015;21:159–165.
   PubMed Web of Science ®Google Scholar
• Salk Institute for Biological Studies. Analogs of fexaramine and methods of making and using. WO2015138969. 2015.
   Google Scholar
• Salk Institute for Biological Studies. FXR agonists and methods for making and using. WO2015138986. 2015.
   Google Scholar
• Salk Institute for Biological Studies. FXR agonists and methods for making and using. US20160376279. 2016.
   Google Scholar
• Salk Institute for Biological Studies. Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors. WO2016149111. 2016.
   Google Scholar
• Metacrine, Inc. Farnesoid X receptor agonists and uses thereof. WO2017049172. 2017.
   Google Scholar
• Metacrine, Inc. Farnesoid X receptor agonists and uses thereof. WO2017049173 (2017)
   Google Scholar
• Metacrine, Inc. Farnesoid X receptor agonists and uses thereof. WO2017049176. 2017.
   Google Scholar
• Metacrine, Inc. Farnesoid X receptor agonists and uses thereof. WO2017049177. 2017.
   Google Scholar
• Flatt B, Martin R, Wang TL, et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem. 2009;52:904–907.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang J, Liu Q, et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380–388.
   PubMed Web of Science ®Google Scholar
• Alios Biopharma, Inc. FXR modulators and methods of their use. WO2017143134. 2017.
   Google Scholar
• Akarna Therapeutics, LTD. Fused bicyclic compounds for the treatment of disease. WO2016081918. 2016.
   Google Scholar
• Akarna Therapeutics, LTD. Combination therapies with farnesoid X receptor (FXR) modulators. WO2017205684. 2017.
   Google Scholar
• Akarna Therapeutics, LTD. Fused bicyclic compounds for the treatment of disease. WO2016151403. 2016.
   Google Scholar
• Akarna Therapeutics, LTD. Fused bicyclic compounds for the treatment of disease. WO2017205633. 2017.
   Google Scholar
• Akarna Therapeutics, LTD. Fused bicyclic compounds for the treatment of disease. WO2016103037. 2016.
   Google Scholar
• IRM LLC. Compositions and methods for modulating farnesoid X receptors. WO2015069666. 2015.
   Google Scholar
• Novartis AG Fused tricyclic pyrazole derivatives useful for modulating farnesoid X receptors. WO2016174616. 2016.
   Google Scholar
• Fiorucci S, Distrutti E, Ricci P, et al. Targeting FXR in cholestasis: hype or hope. Expert Opin Ther Targets. 2014;18:1449–1459.
   PubMed Web of Science ®Google Scholar
• Renga B, Migliorati M, Mencarelli A, et al. Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochim Biophys Acta. 2011;3:157–165.
   Google Scholar
• Fiorucci S, Distrutti E, Bifulco G, et al. Marine sponge steroids as nuclear receptor ligands. Trends Pharmacol Sci. 2012;33:591–601.
   PubMed Web of Science ®Google Scholar
• D’Auria MV, Sepe V, Zampella A. Natural ligands for nuclear receptors: biology and potential therapeutic applications. Curr Top Med Chem. 2012;12:637–669.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Zampella A, Distrutti E. Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders. Curr Top Med Chem. 2012;12:605–624.
   PubMed Web of Science ®Google Scholar
• Renga B, Mencarelli A, D’Amore C, et al. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS One. 2012;7:e30443.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterol. 2016;151:845–859.
   PubMed Web of Science ®Google Scholar
• City of Hope. Farnesoid X receptor antagonists. WO2015116856. 2015.
   Google Scholar
• Randomized global phase 3 study to evaluate the impact on NASH with fibrosis of obeticholic acid treatment. Responsible party: intercept pharmaceuticals, clinicaltrials.Gov identifier: NCT02548351. Available from: https://clinicaltrials.gov/ct2/show/NCT02548351
   Google Scholar